ArticleEuropean journal of immunology2020
LIPS method for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins.
Article in European journal of immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2022Pooled it
- Recent advances in the diagnosis of COVID-19: a bird's eye view.Expert review of molecular diagnostics · 2021Pooled it
- COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain.The Journal of clinical investigation · 2020Trial
- Review
- SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization.Vaccines · 2023Article
- Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing.Biosensors · 2023Review
- The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics.Virology journal · 2023Review
- SARS-CoV-2 accessory proteins reveal distinct serological signatures in children.Nature communications · 2022Article
- Antibody levels remain high to one-year's follow-up after moderate and severe COVID-19, but not after mild cases.Infectious diseases (London, England) · 2022Article
- Diagnostic Performance of Three ELISAs for Detection of Antibodies against SARS-CoV-2 in Human Samples.TheScientificWorldJournal · 2022Article
- Development and evaluation of low-volume tests to detect and characterize antibodies to SARS-CoV-2.Frontiers in immunology · 2022Article
- Development of a highly sensitive Gaussia luciferase immunoprecipitation assay for the detection of antibodies against African swine fever virus.Frontiers in cellular and infection microbiology · 2022Article
- Article
- Serological Detection of SARS-CoV-2 Antibodies in Naturally-Infected Mink and Other Experimentally-Infected Animals.Viruses · 2021Article
- The next-generation coronavirus diagnostic techniques with particular emphasis on the SARS-CoV-2.Journal of medical virology · 2021Review
- Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing.Heliyon · 2021Review
- A Novel Brighter Bioluminescent Fusion Protein Based on ZZ Domain andFrontiers in bioengineering and biotechnology · 2021Article
- Impact of COVID-19 pandemic on EJI and the extended immunological community.European journal of immunology · 2021Article
- Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.Frontiers in cellular and infection microbiology · 2021Article
- Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Profiling antibodies to SARS-CoV-2 can help to assess potential immune response after COVID-19 disease. Luciferase IP system (LIPS) assay is a sensitive method for quantitative detection of antibodies to antigens in their native conformation. We here describe LIPS to detect antibody responses to SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in COVID-19 patients. The antibodies targeted both S and N fragments and gave a high assay sensitivity by identifying 26 out of 26 COVID-19 patients with N antigen or with three protein fragments when combined into a single reaction. The assay correlated well with ELISA method and was specific to COVID-19 as we saw no reactivity among uninfected healthy controls. Our results show that LIPS is a rapid and measurable method to screen antibody responses against SARS-CoV-2 antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.